Cure My Disease

Don't miss your cure!

 Log in / Sign up

New infusion drug aims to keep severe heart failure patients out of hospital

NCT ID NCT00610051

Not yet recruiting Disease control Sponsor: Biopeutics Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a continuous infusion of alprostadil, a drug that widens blood vessels, can help maintain stability in 600 people with advanced heart failure. Participants receive either the drug or a placebo for 6 months. The main goal is to see if the drug reduces deaths, need for heart transplant or mechanical support, and heart failure-related hospitalizations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
alprostadil (a drug that widens blood vessels, given as a continuous infusion)
What this could lead to
If it works, this could provide a new way to keep severe heart failure patients stable and reduce the need for hospitalization or emergency treatment.
What could go wrong
This is still an experimental treatment, and it requires a continuous infusion through a central line, which carries infection and complication risks. The trial is not yet recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE CARDIAC FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE CARDIAC FAILURE HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION NYHF CLASS III-IV

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical university Vienna

    Vienna, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.